Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2011-07-19
2011-07-19
Witherspoon, Sikarl A (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S086000, C564S194000, C548S221000
Reexamination Certificate
active
07982067
ABSTRACT:
Compounds of the formula (II) and (IV) are provided, which may be employed as intermediates for making compounds useful in treating respiratory diseases.
REFERENCES:
patent: 2140800 (1938-12-01), Leemans
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4730008 (1988-03-01), Skidmore et al.
patent: 4853381 (1989-08-01), Finch et al.
patent: 4853382 (1989-08-01), Skidmore et al.
patent: 4908386 (1990-03-01), Finch et al.
patent: 4937268 (1990-06-01), Skidmore et al.
patent: 4963564 (1990-10-01), Skidmore et al.
patent: 4990505 (1991-02-01), Skidmore et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 4997986 (1991-03-01), Mitchell et al.
patent: 5066678 (1991-11-01), Skidmore et al.
patent: 5091422 (1992-02-01), Skidmore et al.
patent: 5099068 (1992-03-01), Mitchell et al.
patent: 5109023 (1992-04-01), Mitchell et al.
patent: 5126375 (1992-06-01), Skidmore et al.
patent: 5225445 (1993-07-01), Skidmore et al.
patent: 5243076 (1993-09-01), Skidmore et al.
patent: 5283262 (1994-02-01), Mitchell et al.
patent: 5290815 (1994-03-01), Johnson et al.
patent: 5393774 (1995-02-01), Pieper et al.
patent: 5552438 (1996-09-01), Christensen, IV
patent: 5998428 (1999-12-01), Barnette et al.
patent: 7135600 (2006-11-01), Biggadike et al.
patent: 7361787 (2008-04-01), Box et al.
patent: 7439393 (2008-10-01), Box et al.
patent: 3513885 (1985-10-01), None
patent: 3524990 (1986-01-01), None
patent: 4028398 (1992-03-01), None
patent: 0069715 (1983-01-01), None
patent: 162576 (1985-11-01), None
patent: 220054 (1987-04-01), None
patent: 220878 (1987-05-01), None
patent: 223410 (1987-05-01), None
patent: 0286242 (1988-10-01), None
patent: 286242 (1988-10-01), None
patent: 303465 (1989-02-01), None
patent: 0317206 (1989-05-01), None
patent: 0416951 (1991-03-01), None
patent: 223671 (1991-11-01), None
patent: 0401966 (1994-01-01), None
patent: 0947498 (1999-10-01), None
patent: 2064336 (1981-06-01), None
patent: 2129691 (1984-05-01), None
patent: 2140800 (1984-12-01), None
patent: 2159151 (1985-11-01), None
patent: 2162842 (1986-02-01), None
patent: 2169265 (1986-07-01), None
patent: 2176476 (1986-12-01), None
patent: 2178965 (1987-02-01), None
patent: 2230523 (1990-10-01), None
patent: 2242134 (1991-09-01), None
patent: 95/01170 (1995-01-01), None
patent: 95/19336 (1995-07-01), None
patent: 99/16766 (1999-04-01), None
patent: 99/47505 (1999-09-01), None
patent: 00/51599 (2000-09-01), None
patent: 01/04118 (2001-01-01), None
patent: 01/13953 (2001-03-01), None
patent: 02/066422 (2002-08-01), None
patent: 02/070490 (2002-09-01), None
patent: 2004/071388 (2004-08-01), None
Dr. Meyer Magarici; Riesgossobre broncodilatadors; SVMS; Nov. 29, 2005.
Drug Bank Chemical Compound Query Result Re Salmeterol; Jul. 31, 2000.
D. Iakovidis, et al.“Synthesis and beta-andrenoceptor agonist properties of (+/−)-1-(3′,4′-dihydroxyphenoxy)-3-(3″,4″-dimethooxyphenyl)ethylamino-2-propanol hydrochloride, (+/−)-(RO363.HCI, and the (2S)-(−)-isomer”; European Journal of Medicinal Chemistry; Jun. 6, 1999; vol. 34, No. 6, pp. 539-548.
Robert Hett, et al., “Enantioselective synthesis of salmeterol via asymmetric borane reduction” Tetrahedron Letters; 1994; vol. 35, No. 50.
U.S. Appl. No. 11/207,967, filed Aug. 19, 2005.
U.S. Appl. No. 11/207,967, final office action dated Jun. 19, 2007.
U.S. Appl. No. 11/426,657, non-final office dated Jun. 25, 2007.
U.S. Appl. No. 11/207,967, non-final office action dated Jan. 11, 2007.
U.S. Appl. No. 11/426,661, non-final office action dated Jan. 12, 2007.
U.S. Appl. No. 11/426,661, non-final office action dated Jul. 5, 2007.
U.S. Appl. No. 11/426,657, non-final office action dated Jan. 12, 2007.
Thornber “Isosterism and molecular modification in drug design” Chemical Society Reviews; 8(4) 563-580, Chemical Society Reviews:8 (4), 563-580, (1979).
U.S. Appl. No. 10/522,321, filed Jul. 6, 2005.
U.S. Appl. No. 11/207,667, filed Aug. 19, 2005.
U.S. Appl. No. 11/426,657, filed Jun. 27, 2006.
U.S. Appl. No. 11/426,661, filed Jun. 27, 2006.
Official Action, date mailed Mar. 15, 2007, U.S. Appl. No. 10/522,321 .
Fuji et al., “Novel phosphodiesterase 4 Inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen” J. Pharmacol Exp Ther 284(1): 162(1998).
Landells et al. “Oral administration of the phosphodiesterase (PDE)4 inhibitor. V11294A Inhibits ex-vivo agonist-induced-cell-activation” Eur Resp J (annu Cong Eur Resp Soc. Geneva) 12(Suppl 28) Abst P2393 (Sep. 1998).
McHale et al. Expressin of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast, Molecular Pharmacology, 39, 109-113 (1991).
Nicholson et al, “Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.” Trends Pharmacol Sci 12: 19-27(1991).
Torphy et al., “Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis” Mol. Pharmacol. 39:376-384 (1991).
Box Philip Charles
Coe Diane Mary
Looker Brian Edgar
Mann Inderjit Singh
Procopiou Panayiotis Alexandrou
Glaxo Group Limited
Smith Robert J.
Witherspoon Sikarl A
LandOfFree
Phenethanolamine derivatives for treatment of respiratory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenethanolamine derivatives for treatment of respiratory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenethanolamine derivatives for treatment of respiratory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734869